Literature DB >> 11583897

Differences in inducibility and prognosis of in-hospital versus out-of-hospital identified nonsustained ventricular tachycardia in patients with coronary artery disease: clinical and trial design implications.

L A Pires1, M H Lehmann, A E Buxton, G E Hafley, K L Lee.   

Abstract

OBJECTIVES: The goal of this study was to describe the influence of the clinical setting (in-hospital vs. out-of-hospital) in which nonsustained ventricular tachycardia (NSVT) is discovered on the rate of inducibility of sustained ventricular tachycardia (VT), arrhythmic events and survival in patients with coronary artery disease (CAD) and left ventricular (LV) dysfunction.
BACKGROUND: In-hospital presentation of sustained VT is independently associated with lower long-term overall survival. The impact of the clinical setting in which NSVT is documented is unknown.
METHODS: In the Multicenter Unsustained Tachycardia Trial (MUSTT), designed to assess the benefit of randomized antiarrhythmic therapy guided by electrophysiologic testing in patients with asymptomatic NSVT, CAD and LV dysfunction, eligible patients were enrolled irrespective of the setting in which the index arrhythmia was discovered. In this retrospective analysis, we compared the rate of VT inducibility and outcome of MUSTT-enrolled patients with in-hospital versus out-of-hospital presentation of NSVT.
RESULTS: Monomorphic sustained VT was induced in 35% and 28% of the patients whose index NSVT occurred in-hospital and out-of-hospital, respectively (adjusted p = 0.006). Cardiac arrest or death due to arrhythmia at two- and five-year follow-ups were 14% and 28% for untreated patients with in-hospital-identified NSVT and 11% and 21% for the out-of-hospital group (adjusted p = 0.10). Overall mortality rates at two- and five-year follow-ups were 24% and 48% for inpatients and 18% and 38% for outpatients (adjusted p = 0.018). In patients randomized to antiarrhythmic therapy, there was no significant interaction between patient status (in-hospital vs. out-of-hospital) and treatment impact on the rates of total mortality (p = 0.98) and arrhythmic events (p = 0.08).
CONCLUSIONS: In patients with CAD and impaired LV function, asymptomatic NSVT identified in-hospital, compared with that identified out-of-hospital, is associated with a higher rate of induction of sustained VT and overall mortality. Therefore, in similar patients, the clinical setting in which NSVT is discovered should be taken into account when formulating patient risk, treatment and clinical trial design.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583897     DOI: 10.1016/s0735-1097(01)01482-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduce ventricular arrhythmia.

Authors:  Dalit Weisman; Roy Beinart; Aharon Erez; Nira Koren-Morag; Ilan Goldenberg; Michael Eldar; Michael Glikson; David Luria
Journal:  J Interv Card Electrophysiol       Date:  2017-06-29       Impact factor: 1.900

2.  Risk stratification for serious arrhythmic events using nonsustained ventricular tachycardia and heart rate turbulence detected by 24-hour holter electrocardiograms in patients with left ventricular dysfunction.

Authors:  Yosuke Miwa; Hideaki Yoshino; Kyoko Hoshida; Mutsumi Miyakoshi; Takehiro Tsukada; Satoru Yusu; Takanori Ikeda
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-07       Impact factor: 1.468

3.  2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry.

Authors:  Jonathan S Steinberg; Niraj Varma; Iwona Cygankiewicz; Peter Aziz; Paweł Balsam; Adrian Baranchuk; Daniel J Cantillon; Polychronis Dilaveris; Sergio J Dubner; Nabil El-Sherif; Jaroslaw Krol; Malgorzata Kurpesa; Maria Teresa La Rovere; Suave S Lobodzinski; Emanuela T Locati; Suneet Mittal; Brian Olshansky; Ewa Piotrowicz; Leslie Saxon; Peter H Stone; Larisa Tereshchenko; Mintu P Turakhia; Gioia Turitto; Neil J Wimmer; Richard L Verrier; Wojciech Zareba; Ryszard Piotrowicz
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05       Impact factor: 1.468

4.  Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).

Authors:  Jay Chen; George Johnson; Anne S Hellkamp; Jill Anderson; Daniel B Mark; Kerry L Lee; Gust H Bardy; Jeanne E Poole
Journal:  J Am Coll Cardiol       Date:  2013-03-26       Impact factor: 24.094

5.  Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT).

Authors:  John D Fisher; Alfred E Buxton; Kerry L Lee; Douglas L Packer; Debra S Echt; Pablo Denes; Michael H Lehmann; John P DiMarco; Denis Roy; Gail E Hafley
Journal:  Am J Cardiol       Date:  2007-05-11       Impact factor: 2.778

6.  Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function.

Authors:  Tomas Konecny; Kiran R Somers; Jae Yoon Park; Alan John; Marek Orban; Rahul Doshi; Paul D Scanlon; Samuel J Asirvatham; Charanjit S Rihal; Peter A Brady
Journal:  Heart Rhythm       Date:  2017-10-03       Impact factor: 6.343

7.  Exercise induced non-sustained ventricular tachycardia and indication for invasive management.

Authors:  Shahriar Dadkhah; Samaneh Dowlatshahi; Korosh Sharain; Roza Sharain
Journal:  Clin Med Insights Cardiol       Date:  2011-11-17

8.  Prognostic significance of nonsustained ventricular tachycardia in patients receiving cardiac resynchronization therapy for primary prevention: Analysis of the Japan cardiac device treatment registry database.

Authors:  Hisashi Yokoshiki; Akihiko Shimizu; Takeshi Mitsuhashi; Hiroshi Furushima; Yukio Sekiguchi; Tetsuyuki Manaka; Nobuhiro Nishii; Takeshi Ueyama; Norishige Morita; Hideo Okamura; Takashi Nitta; Kenzo Hirao; Ken Okumura
Journal:  J Arrhythm       Date:  2018-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.